Ontology highlight
ABSTRACT:
SUBMITTER: Foster GR
PROVIDER: S-EPMC4990525 | biostudies-literature | 2016
REPOSITORIES: biostudies-literature
Foster Graham R GR Chayama Kazuaki K Chuang Wan-Long WL Fainboim Hugo H Farkkila Martti M Gadano Adrian A Gaeta Giovanni B GB Hézode Christophe C Inada Yukiko Y Heo Jeong J Kumada Hiromitsu H Lu Sheng-Nan SN Marcellin Patrick P Moreno Christophe C Roberts Stuart K SK Strasser Simone I SI Thompson Alexander J AJ Toyota Joji J Paik Seung Woon SW Vierling John M JM Zignego Anna L AL Cohen David D McPhee Fiona F Wind-Rotolo Megan M Srinivasan Subasree S Hruska Matthew M Myler Heather H Portsmouth Simon D SD
SpringerPlus 20160819 1
<h4>Background and purpose</h4>Peginterferon Lambda was being developed as an alternative to alfa interferon for the treatment of chronic hepatitis C virus (HCV) infection. We compared peginterferon Lambda-1a plus ribavirin (Lambda/RBV) and Lambda/RBV plus daclatasvir (DCV; pangenotypic NS5A inhibitor) with peginterferon alfa-2a plus RBV (alfa/RBV) in treatment-naive patients with HCV genotype 2 or 3 infection.<h4>Methods</h4>In this multicenter, double-blind, phase 3 randomized controlled trial ...[more]